Mr Michal Rokicki
Research Assistant, Dementia Research Institute
- RokickiM@cardiff.ac.uk
- +44 29207 44184/46922
- Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ
Publication
2022
- Chiriches, C. et al. 2022. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia. Annals of Hematology 101, pp. 2179-2193. (10.1007/s00277-022-04905-9)
2016
- Davis, T., Brook, A. J. C., Rokicki, M. J., Bagley, M. and Kipling, D. G. 2016. Evaluating the role of p38 MAPK in the accelerated cell senescence of Werner syndrome fibroblasts. Pharmaceuticals 9(2), article number: 23. (10.3390/ph9020023)
2013
- Tivey, H. S. E., Brook, A. J. C., Rokicki, M. J., Kipling, D. G. and Davis, T. 2013. p38 MAPK stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes. Biogerontology 14(1), pp. 47-62. (10.1007/s10522-012-9407-2)
- Davis, T., Rokicki, M. J., Bagley, M. C. and Kipling, D. G. 2013. The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome. Chemistry Central Journal 7, article number: 18. (10.1186/1752-153X-7-18)
- Davis, T., Tivey, H., Brook, A. J. C., Grimstead, J. W., Rokicki, M. J. and Kipling, D. G. 2013. Activation of p38 MAP kinase and stress signalling in fibroblasts from the progeroid Rothmund-Thomson syndrome. AGE 35(5), pp. 1767-1783. (10.1007/s11357-012-9476-9)
- Tivey, H. S. E., Rokicki, M. J., Barnacle, J. R., Rogers, M. J., Bagley, M. C., Kipling, D. G. and Davis, T. 2013. Small molecule inhibition of p38 MAP kinase extends the replicative life span of human ATR-Seckel syndrome fibroblasts. The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 68(9), pp. 1001-1009. (10.1093/gerona/gls336)
2011
- Davis, T., Dix, M. C., Rokicki, M. J., Brook, A. J. C., Widdowson, C. S., Kipling, D. G. and Bagley, M. C. 2011. Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors. Chemistry Central Journal 5(1), pp. 83-88. (10.1186/1752-153X-5-83)
2010
- Bagley, M. C., Davis, T., Dix, M., Fusillo, V., Pigeaux, M., Rokicki, M. J. and Kipling, D. G. 2010. Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome. Future Medicinal Chemistry 2(9), pp. 1417-1427. (10.4155/fmc.10.217)
- Bagley, M. C., Davis, T., Rokicki, M. J., Widdowson, C. S. and Kipling, D. G. 2010. Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome. Future Medicinal Chemistry 2(2), pp. 193-201. (10.4155/fmc.09.163)
- Bagley, M. C., Davis, T., Dix, M. C., Murziani, P. G. S., Rokicki, M. J. and Kipling, D. G. 2010. Microwave-assisted synthesis of a pyrazolyl ketone library for evaluation as p38 MAPK inhibitors in Werner syndrome cells. Future Medicinal Chemistry 2(2), pp. 203-213. (10.4155/fmc.09.160)
2009
- Bagley, M. C., Davis, T., Dix, M. C., Fusillo, V., Pigeaux, M., Rokicki, M. J. and Kipling, D. G. 2009. Microwave-assisted Ullmann C-S bond formation: synthesis of the P38 alpha MAPK clinical candidate VX-745. Journal of Organic Chemistry 74(21), pp. 8336-8342. (10.1021/jo9017155)
2008
- Bagley, M. C., Davis, T., Dix, M. C., Murziani, P. G. S., Rokicki, M. J. and Kipling, D. G. 2008. Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. Bioorganic & Medicinal Chemistry Letters 18(13), pp. 3745-3748. (10.1016/j.bmcl.2008.05.037)
2007
- Bagley, M. C., Davis, T., Dix, M., Rokicki, M. J. and Kipling, D. G. 2007. Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Biorganic and Medicinal Chemistry Letters 17(18), pp. 5107-5110. (10.1016/j.bmcl.2007.07.016)
- Davis, T., Wyllie, F. S., Rokicki, M. J., Bagley, M. C. and Kipling, D. G. 2007. The Role of Cellular Senescence in Werner Syndrome: Toward Therapeutic Intervention in Human Premature Aging. Annals of the New York Academy of Sciences 1100, pp. 455-469. (10.1196/annals.1395.051)
Articles
- Chiriches, C. et al. 2022. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia. Annals of Hematology 101, pp. 2179-2193. (10.1007/s00277-022-04905-9)
- Davis, T., Brook, A. J. C., Rokicki, M. J., Bagley, M. and Kipling, D. G. 2016. Evaluating the role of p38 MAPK in the accelerated cell senescence of Werner syndrome fibroblasts. Pharmaceuticals 9(2), article number: 23. (10.3390/ph9020023)
- Tivey, H. S. E., Brook, A. J. C., Rokicki, M. J., Kipling, D. G. and Davis, T. 2013. p38 MAPK stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes. Biogerontology 14(1), pp. 47-62. (10.1007/s10522-012-9407-2)
- Davis, T., Rokicki, M. J., Bagley, M. C. and Kipling, D. G. 2013. The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome. Chemistry Central Journal 7, article number: 18. (10.1186/1752-153X-7-18)
- Davis, T., Tivey, H., Brook, A. J. C., Grimstead, J. W., Rokicki, M. J. and Kipling, D. G. 2013. Activation of p38 MAP kinase and stress signalling in fibroblasts from the progeroid Rothmund-Thomson syndrome. AGE 35(5), pp. 1767-1783. (10.1007/s11357-012-9476-9)
- Tivey, H. S. E., Rokicki, M. J., Barnacle, J. R., Rogers, M. J., Bagley, M. C., Kipling, D. G. and Davis, T. 2013. Small molecule inhibition of p38 MAP kinase extends the replicative life span of human ATR-Seckel syndrome fibroblasts. The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 68(9), pp. 1001-1009. (10.1093/gerona/gls336)
- Davis, T., Dix, M. C., Rokicki, M. J., Brook, A. J. C., Widdowson, C. S., Kipling, D. G. and Bagley, M. C. 2011. Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors. Chemistry Central Journal 5(1), pp. 83-88. (10.1186/1752-153X-5-83)
- Bagley, M. C., Davis, T., Dix, M., Fusillo, V., Pigeaux, M., Rokicki, M. J. and Kipling, D. G. 2010. Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome. Future Medicinal Chemistry 2(9), pp. 1417-1427. (10.4155/fmc.10.217)
- Bagley, M. C., Davis, T., Rokicki, M. J., Widdowson, C. S. and Kipling, D. G. 2010. Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome. Future Medicinal Chemistry 2(2), pp. 193-201. (10.4155/fmc.09.163)
- Bagley, M. C., Davis, T., Dix, M. C., Murziani, P. G. S., Rokicki, M. J. and Kipling, D. G. 2010. Microwave-assisted synthesis of a pyrazolyl ketone library for evaluation as p38 MAPK inhibitors in Werner syndrome cells. Future Medicinal Chemistry 2(2), pp. 203-213. (10.4155/fmc.09.160)
- Bagley, M. C., Davis, T., Dix, M. C., Fusillo, V., Pigeaux, M., Rokicki, M. J. and Kipling, D. G. 2009. Microwave-assisted Ullmann C-S bond formation: synthesis of the P38 alpha MAPK clinical candidate VX-745. Journal of Organic Chemistry 74(21), pp. 8336-8342. (10.1021/jo9017155)
- Bagley, M. C., Davis, T., Dix, M. C., Murziani, P. G. S., Rokicki, M. J. and Kipling, D. G. 2008. Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. Bioorganic & Medicinal Chemistry Letters 18(13), pp. 3745-3748. (10.1016/j.bmcl.2008.05.037)
- Bagley, M. C., Davis, T., Dix, M., Rokicki, M. J. and Kipling, D. G. 2007. Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Biorganic and Medicinal Chemistry Letters 17(18), pp. 5107-5110. (10.1016/j.bmcl.2007.07.016)
- Davis, T., Wyllie, F. S., Rokicki, M. J., Bagley, M. C. and Kipling, D. G. 2007. The Role of Cellular Senescence in Werner Syndrome: Toward Therapeutic Intervention in Human Premature Aging. Annals of the New York Academy of Sciences 1100, pp. 455-469. (10.1196/annals.1395.051)